FDA grants EUA for Pfizer-BioNTech’s Covid-19 booster in children
The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…

The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
The approval is based on findings from the Phase III SURPASS programme of Mounjaro.
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
On Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.
Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.